NG9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Top-line GrowthSustained revenue scaling over multiple years demonstrates durable demand for NeoGenomics' oncology testing mix and commercial traction across clinical and pharma segments. Growing top line supports capacity investments, improves operating leverage potential and underpins multi‑year margin recovery if mix and pricing trends persist.
NGS Mix ExpansionRapid NGS growth and rising share of clinical revenue is a structural positive: higher‑complexity molecular assays generally carry better pricing and strategic stickiness with oncologists and pharma. A durable mix shift toward NGS supports higher AUP, margin expansion, and deeper integration into precision oncology workflows over the medium term.
Refinancing & Liquidity ActionsProactive capital‑markets actions—issuing longer‑dated convertibles while repurchasing near‑term paper—extend maturities and reduce refinancing pressure. Coupled with improving operating cash flow and substantial equity, this materially lowers near‑term liquidity risk and preserves runway for commercial investment and R&D.
Bears Say
Ongoing LossesDespite revenue gains, persistent negative operating and net margins indicate NeoGenomics has yet to deliver consistent profitability. Continued losses constrain internal capital generation, depress returns on equity, and require ongoing external financing or dilution until margins sustainably turn positive and free cash flow becomes reliably positive.
Reimbursement & Payer RiskNew product approvals don't guarantee rapid monetization: delayed commercial payer coverage and reimbursement timing can materially slow adoption and revenue realization for liquid biopsy and MRD offerings. Structural lag in payer policy adoption can compress near‑term margins and slow breakeven on R&D/commercial investments.
Pharma Services WeaknessA meaningful decline in biopharma services reduces revenue diversification and exposes the company to clinical cyclicality. If pharma services remain soft, NeoGenomics must rely more heavily on clinical testing growth to meet guidance, making results more sensitive to clinical volumes, reimbursement and test mix rather than balanced segment performance.
NeoGenomics News
NG9 FAQ
What was NeoGenomics’s price range in the past 12 months?
Currently, no data Available
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is CHF1.71B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 10, 2026 which is in 87 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 28, 2026. The company reported CHF0.041 earnings per share for the quarter, beating the consensus estimate of CHF0.028 by CHF0.013.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.04.
How many shares outstanding does NeoGenomics have?
Currently, no data Available
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of CHF0.041 in its last earnings report, beating expectations of CHF0.028. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in CH:NG9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF14.41 (― Upside)
CHF14.41 (― Upside)
Blogger Sentiment
Bullish
CH:NG9 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF358.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.99%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NG9 Company Deck
NG9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.View all CH:NG9 earnings summaries